Introduction: The necessity for tuberculosis preventive treatment (TPT) and routine T-SPOT.TB monitoring in patients with psoriasis and tuberculosis infection (TBI) undergoing interleukin (IL)-17A inhibitor therapy remains uncertain. This study aims to evaluate the long-term safety of IL-17A inhibitors administered without TPT and analyze changes in T-SPOT.TB among these patients. It also identifies risk factors for TBI in patients with psoriasis.
Methods: This single-center prospective study enrolled adult patients with plaque psoriasis and TBI receiving IL-17A inhibitors. TBI was defined as positive T-SPOT.TB results (≥ 6 spots) without symptoms or evidence of active tuberculosis (ATB). TPT administration was based on contraindications, tuberculosis risk factors, and patient preferences. The primary endpoint was the incidence of ATB over 2 years. Secondary outcomes included T-SPOT.TB changes and TBI risk factors.
Results: Of the 129 patients with psoriasis and TBI enrolled in the study, 97 (75.2%) did not receive TPT, while 32 (24.8%) did. Among them, 109 patients (84.5%) completed the 2-year follow-up. During the 235 person-years of observation, no ATB cases were identified. Median T-SPOT.TB values showed no significant changes from baseline to year 2 in both the non-TPT (20 vs. 17 spots, p = 0.975) and TPT groups (55 vs. 58 spots, p = 0.830). T-SPOT.TB reversed in 14 patients (12.8%), mostly in the non-TPT group. Moreover, for TBI risk factor analysis, a cohort of 212 patients with psoriasis with negative baseline T-SPOT.TB was evaluated, revealing a TBI prevalence of 37.8%. Logistic regression analysis highlighted age ≥ 45 years (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.50-3.99, p < 0.001) and body mass index (BMI) < 24.0 kg/m (OR 2.12, 95% CI 1.27-3.54, p = 0.004) as independent risk factors for TBI.
Conclusion: IL-17A inhibitors do not appear to reactivate tuberculosis in patients with psoriasis and TBI, potentially reducing the need for routine TBI screening and preventive treatment.
Trial Registration: Chinese Clinical Trial Registry, ChiCTR2100045823.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11052946 | PMC |
| http://dx.doi.org/10.1007/s13555-024-01130-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eruption of Generalized Pustular Psoriasis Following Initiation of Adalimumab for Hidradenitis Suppurativa: A Case Report.
Cureus
December 2024
Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Rarely, tumor necrosis factor (TNF)-α inhibitors can paradoxically induce eruptions of psoriasis with generalized pustular psoriasis being among the least common presentations. We report a patient who presented with a generalized pustular eruption following adalimumab therapy for hidradenitis suppurativa (HS). The diagnosis of generalized pustular psoriasis was confirmed with a biopsy showing neutrophilic spongiosis and intraepidermal pustulosis.
View Article and Find Full Text PDFBreakthrough Psoriasis in Patients Receiving Biologicals.
Psoriasis (Auckl)
January 2025
Department of Dermatology and Venerology, CHU of Sart Tilman, University of Liège B-4000, Liège, Belgium.
Background: Biological therapies, including TNF-alpha, IL12/23, IL17 and IL23 antagonists, adequately control a very high number of patients with moderate-to-severe psoriasis with an excellent long-term safety profile. However, on occasion, patients on biological therapy with stabilized disease or complete remission report episodes of sudden breakthrough psoriasis.
Aim: To study prospectively in a monocentric tertiary setting, the clinical characteristics of patients presenting a sudden breakthrough psoriasis although completely stabilized (PASI 90-100) under biological therapy.
Weight-Adjusted Waist Index, Psoriasis, and All-Cause Mortality: Findings from the NHANES 2003-2006 and 2009-2014.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Purpose: Psoriasis is associated with obesity, which in turn is linked to increased mortality risk. Therefore, we undertook a cohort study utilizing data from the National Health and Nutrition Examination Survey (NHANES) to examine the impact of weight-adjusted waist index (WWI) on the likelihood of all-cause mortality in psoriasis individuals.
Patients And Methods: This study utilized data from the National Health and Nutrition Examination Survey (NHANES) to investigate the influence of WWI on the probability of all-cause mortality in psoriasis individuals.
Proteomic Analysis of Mesenchymal Stem Cell-derived Exosomes in Psoriasis.
Curr Mol Med
January 2025
Shanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Department of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Purpose: This study aims to investigate the unique proteins in exosomes from mesenchymal stem cells derived from psoriatic lesions and compare them with those from healthy human skin. It seeks to identify potential regulatory factors that may influence the differential effects observed in these exosomes.
Methods: Dermal mesenchymal stem cell exosomes were isolated from healthy human skin (HDMSCs-EXO) and psoriatic lesion of patient (PDMSCs-EXO).
Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis.
RMD Open
January 2025
Department of Rheumatology, UZ Leuven, Leuven, Belgium.
Objectives: To investigate serum lipid profile in early, treatment-naïve psoriatic arthritis (PsA) and to determine whether changes in classical lipids or apolipoproteins are specific to PsA.
Methods: Total cholesterol, non-high-density lipoprotein cholesterol (non-HDL-c), low-density lipoprotein cholesterol (LDL-c), HDL-c, triglycerides, apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) were compared in newly diagnosed untreated PsA patients (n=75) to sex- and age-matched controls (healthy control (HC)) (n=61) and early untreated rheumatoid arthritis (RA) patients (n=50).
Results: Among classical lipid measurements, HDL-c levels were lower in PsA than in HC and RA (df 2, χ10, p=0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!